Fund managers back market darling Telix Pharmaceuticals

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 90%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

A bevvy of healthcare analysts and Australian equities managers have profited from buying fast-rising oncology business Telix, after it unveiled strong sales.

Shares in Telix Pharmaceuticals have surged more than tenfold in five years as a record June quarter of sales supports phenomenal investor interest in the cancer diagnostic and treatment business.

Antares is among Australian equities managers such as Platinum Asset Management, Perennial Partners, Fidelity, Acorn Capital, and Wilson Asset Management that own Telix shares. “We still think shares have further upside,” said Mr Hamilton. “I think that first [June] quarter of commercial sales in Illucix show it’s a great product. It entered the market and got very good awareness of PSMA imaging.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

tommyr345 still a puppet for asxlongtail Only biotech Tom covers strangely, share price is the same as last time you wrote a puff piece for him 🤡

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 2. in İD

Indonesia Berita Terbaru, Indonesia Berita utama